These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27067319)

  • 1. Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing.
    Rivera CG; Narayanan PP; Patel R; Estes LL
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3854-5. PubMed ID: 27067319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT; Heil EL; Leekha S; Fowler RC; Hanson ND; Majumdar A; Johnson JK
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various Minimum Inhibitory Concentrations.
    Altshuler J; Guervil DJ; Ericsson CD; Wanger A; Aitken SL; Ostrosky-Zeichner L
    J Pharm Pract; 2018 Feb; 31(1):34-39. PubMed ID: 29278990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
    Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians.
    Fouad A; Gill CM; Simner PJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2023 Sep; 78(9):2242-2253. PubMed ID: 37522258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secular trends associated with Enterobacteriaceae with a cefepime susceptible-dose-dependent MIC.
    Wagner JL; Kenney RM; Tibbetts RJ; Davis SL
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1822-3. PubMed ID: 25512418
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
    Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
    Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?
    Menegucci TC; Bastos MS; Viana GF; Moreira RRB; Garcia LB; Cardoso CL; Tognim MCB
    J Chemother; 2017 Jun; 29(3):189-194. PubMed ID: 27077929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.
    Tamma PD; Girdwood SC; Gopaul R; Tekle T; Roberts AA; Harris AD; Cosgrove SE; Carroll KC
    Clin Infect Dis; 2013 Sep; 57(6):781-8. PubMed ID: 23759352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa.
    Hamada Y; Sutherland CA; Nicolau DP
    J Clin Microbiol; 2015 May; 53(5):1712-4. PubMed ID: 25694527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2015 May; 59(5):2688-94. PubMed ID: 25712356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
    Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.